Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

915.41 -9.19 (-0.99%)

Streaming Delayed Price Updated: 3:23 PM EDT, Jul 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers ↗

July 17, 2023

Big gains are afoot even as the markets prepare for a flat open.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 17, 2023

Via Benzinga

Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket ↗

July 17, 2023

Gainers

Via Benzinga

Why Is BYND Cannasoft Enterprise (BCAN) Stock Down 46% Today? ↗

July 17, 2023

BYND Cannasoft Enterprise (BCAN) stock is dropping on Monday after the company announced an underwritten stock offering.

Via InvestorPlace

Why Are Argenx Shares Trading Higher Today? ↗

July 17, 2023

Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory

Via Benzinga

Why Is Argenx (ARGX) Stock Up 27% Today? ↗

July 17, 2023

Argenx (ARGX) stock is climbing higher on Monday following the release of data from a Phase 1 clinical trial of VYVGART Hytrulo.

Via InvestorPlace

The Latest Analyst Ratings for argenx ↗

June 07, 2023

Via Benzinga

Analyst Expectations for argenx's Future ↗

June 07, 2023

Via Benzinga

Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today? ↗

July 17, 2023

Quoin Pharmaceuticals (QNRX) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

July 17, 2023

It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!

Via InvestorPlace

Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 17, 2023

U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

July 17, 2023

From Zai Lab Limited

Via GlobeNewswire

Expert Ratings for argenx ↗

May 31, 2023

Via Benzinga

argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

July 17, 2023

From argenx SE

Via GlobeNewswire

This Emerging Market Could Be the Next Big Thing in Biotech ↗

July 14, 2023

Medicines to treat the many symptoms of long COVID are in high demand already.

Via The Motley Fool

Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration ↗

July 08, 2023

F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...

Via Talk Markets

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

June 30, 2023

From argenx SE

Via GlobeNewswire

Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

June 30, 2023

From Zai Lab Limited

Via GlobeNewswire

FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults ↗

June 27, 2023

The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or...

Via Benzinga

AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease ↗

June 26, 2023

The European Union has reco

Via Benzinga

Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis ↗

June 21, 2023

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...

Via Benzinga

argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis

June 20, 2023

From argenx SE

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 20, 2023

Via Benzinga

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

June 20, 2023

From argenx SE

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023 ↗

May 31, 2023

Via Benzinga

argenx to Present at Upcoming Investor Conferences

May 31, 2023

From argenx SE

Via GlobeNewswire

Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday ↗

May 05, 2023

Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares...

Via Benzinga

argenx Reports First Quarter 2023 Financial Results and Provides Business Update

May 04, 2023

From argenx SE

Via GlobeNewswire

argenx announces results of Annual General Meeting of Shareholders

May 03, 2023

From argenx SE

Via GlobeNewswire

argenx to Present at BofA Securities 2023 Health Care Conference

May 02, 2023

From argenx SE

Via GlobeNewswire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.